PAUL E KLOTMAN, MD
Osteopathic Medicine in New York, NY
License number
New York 199427
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
5 EAST 98. St, New York, NY 10029
Phone
(212) 241-4060
(212) 987-0389 (Fax)
(212) 987-0389 (Fax)
Personal information
See more information about PAUL E KLOTMAN at radaris.comName
Address
Phone
387 W End Ave, New York, NY 10024
New York, NY
387 End Ave, New York, NY 10024
387 W End Ave, New York, NY 10024
424 End Ave, New York, NY 10024
Organization information
See more information about PAUL E KLOTMAN at bizstanding.comMount Sinai Hospital - Paul E Klotman MD
1 Gustave L Levy Pl, New York, NY 10029
Categories:
Internal Medicine Physicians & Surgeons, Nephrology Physicians & Surgeons
Phone:
(212) 241-6500 (Phone)
Professional information
Chairman, Department Of Medicine At Mount Sinai Medical Center
Position:
CEO and President, Baylor College of Medicine at Mount Sinai Hospital, New York
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Work:
Mount Sinai Hospital, New York
since Sep 2010
-
CEO and President, Baylor College of Medicine
Mount Sinai Medical Center
Oct 2001 - Sep 2010
-
Chairman, Department of Medicine
Paul E Klotman, New York NY
Specialties:
Nephrologist
Address:
5 E 98Th St, New York, NY 10029
1 Gustave L Levy Pl, New York, NY 10029
1 Gustave L Levy Pl, New York, NY 10029
Education:
Indiana University, School of Medicine - Doctor of Medicine
Duke University Hospital - Fellowship - Nephrology (Internal Medicine)
Duke University Hospital - Residency - Family Medicine
Duke University Hospital - Fellowship - Nephrology (Internal Medicine)
Duke University Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)
Dr. Paul E Klotman - MD (Doctor of Medicine)
Hospitals:
5 E 98Th St, New York 10029
5 E 98Th St, New York 10029
5 E 98Th St, New York 10029
Education:
Medical Schools
Indiana University School Of Medicine
Graduated: 1976
Indiana University School Of Medicine
Graduated: 1976
Use Of Podocan Protein In Treating Cardiovascular Diseases
US Patent:
2011005, Mar 3, 2011
Filed:
Dec 19, 2008
Appl. No.:
12/809899
Inventors:
Paul Klotman - New York NY, US
Randolph Hutter - New York NY, US
Li Huang - New York NY, US
Randolph Hutter - New York NY, US
Li Huang - New York NY, US
International Classification:
A61K 38/02, A61P 9/12, A61P 9/00
US Classification:
514 157, 514 11
Abstract:
The present invention relates to compositions and methods for the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant vasculopathy, and pulmonary hypertension More particularly, the present invention relates to methods and pharmaceutical compositions for delivering podocan or podocan inhibitors to the arterial system of an animal, thus resulting in the down-regulation or up-regulation, respectively, of smooth muscle cell (SMC) functions such as SMC proliferation and migration Up-regulation of vascular smooth muscle cell proliferation and/or migration by podocan inhibition results in the treatment of vulnerable plaques, while down-regulation of vascular smooth muscle cell proliferation and/or migration via podocan delivery and/or up-regulation results in the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant or graft vasculopathy and pulmonary hypertension.
Treatment And Prevention Of Renal Disease
US Patent:
2009022, Sep 3, 2009
Filed:
Feb 13, 2007
Appl. No.:
12/279128
Inventors:
Michael J. Ross - Hastings-on-hudson NY, US
Paul E. Klotman - New York NY, US
Mary E. Klotman - New York NY, US
Paul E. Klotman - New York NY, US
Mary E. Klotman - New York NY, US
Assignee:
MOUNT SINAI SCHOOL OF MEDICINE - New York NY
International Classification:
A61K 39/395, C12Q 1/68
US Classification:
4241391, 435 6
Abstract:
The present invention is directed to a method of treating or preventing renal disease in a subject. This method involves administering the subject an agent which inhibits FAT10 expression in the subject under conditions effective to prevent or treat renal disease. Also disclosed is a method of screening for agents effective in treating or preventing renal disease.
Methods And Compositions For The Treatment Of Disorders Of Hiv Infection
US Patent:
2003022, Dec 11, 2003
Filed:
Apr 14, 2003
Appl. No.:
10/413785
Inventors:
Irwin Gelman - Buffalo NY, US
Paul Klotman - New York NY, US
Ming Zhou - Old Greenwich CT, US
Paul Klotman - New York NY, US
Ming Zhou - Old Greenwich CT, US
International Classification:
A01K067/00, C12Q001/70, A61K039/395, C12N015/867
US Classification:
800/008000, 424/145100, 435/005000, 435/325000, 435/456000
Abstract:
The present invention relates to methods and compositions for use in the intervention of diseases associated with HIV infection. In exemplary embodiments, methods and compositions for the treatment of HIV associated nephropathy (HIVAN) are disclosed.